The FDA has requested additional data related to chemistry, manufacturing, and controls (CMC) and contract manufacturing facilities; no clinical safety or efficacy concerns were identified that impact ...
Pharmaceutical Technology on MSN
FDA issues complete response letter to Sobi’s NASP for gout
The FDA did not identify concerns about the clinical efficacy or safety of NASP that would affect its potential for approval.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results